Abstract
Background: Despite the rapid growth of fluorescence imaging, accurate sampling of tissue sections remains challenging. Development of novel technologies to improve intraoperative assessment of tissue is needed. Methods: A novel contact probe-based fluorescence dosimeter device, optimized for IRDye800CW quantification, was developed. After evaluation of the device in a phantom setup, its clinical value was defined ex vivo in patients with head and neck squamous cell carcinoma who received panitumumab-IRDye800CW. Results: Ten patients were enrolled with a total of 216 data points obtained. Final histopathology showed tumor in 119 spots and normal tissue in 97 spots. Fluorescence-to-excitation ratios in tumor tissue were more than three times higher than those in normal tissue. The area under the curve was 0.86 (95% CI: 0.81-0.91) for tumor detection. Conclusions: Fluorescence-guided tissue preselection using a fluorescence dosimeter could have substantial impact on tissue sampling for frozen section analysis and potentially reduce sampling errors.
Original language | English |
---|---|
Pages (from-to) | 59-66 |
Number of pages | 8 |
Journal | Head and Neck |
Volume | 42 |
Issue number | 1 |
Early online date | 1 Oct 2019 |
DOIs | |
Publication status | Published - Jan 2020 |
Bibliographical note
Funding Information:This work was supported in part by the Stanford Comprehensive Cancer Center, the Stanford University School of Medicine Medical Scholars Program, the Netherlands Organization for Scientific Research (Rubicon; 019.171LW.022), the National Institutes of Health and the National Cancer Institute (R01CA190306), and the Stanford Molecular Imaging Scholars (SMIS) program (T32 CA118681).
Publisher Copyright:
© 2019 Wiley Periodicals, Inc.
Keywords
- EGFR
- fluorescence dosimetry
- fluorescence-guided tissue preselection
- head and neck cancer
- panitumumab